Xianju Pharmaceutical announced that the company participated in the 12th batch of centralized procurement bidding for national drugs on July 31, 2026. The products drospirenone tablets, didroprogesterone tablets, and betastine mesylate tablets will be selected. The procurement cycle for the products to be selected is from the date of implementation of the selected results to December 31, 2029. In 2025, the domestic sales amount for drospirenone ethinylestradiol tablets was about 48.58 million yuan, and didroprogesterone tablets were about 3.412,200 yuan; betahistine mesylate tablets were approved for sale in May 2026. The final results are subject to publication by the Joint Procurement Office.

Xianju Pharmaceutical announced that the company participated in the 12th batch of centralized procurement bidding for national drugs on July 31, 2026. The products drospirenone tablets, didroprogesterone tablets, and betastine mesylate tablets will be selected. The procurement cycle for the products to be selected is from the date of implementation of the selected results to December 31, 2029. In 2025, the domestic sales amount for drospirenone ethinylestradiol tablets was about 48.58 million yuan, and didroprogesterone tablets were about 3.412,200 yuan; betahistine mesylate tablets were approved in May 2026, and there is no sale yet. The final results are subject to publication by the Joint Procurement Office.